How Hormone Therapy Amplifies Tirzepatide and Semaglutide Weight Loss After Menopause

Ashley Harwyn, PA-C  |  A4M Board Certified  |  June 10, 2026

This is the most common scenario among the postmenopausal women who come to my Charleston practice from national telehealth Wegovy and Mounjaro programs. The plateau is rarely about dose, and it is never about motivation. For many postmenopausal women, the limiting factor is estrogen, and the January 2026 Mayo Clinic research is the first to quantify how much that matters.

In January 2026, Mayo Clinic researchers published a finding in The Lancet OB/GYN and Women's Health that explains the plateau experienced by roughly half the postmenopausal women on GLP-1 medications nationwide. The finding is precise. The intervention it points to is well-tolerated, FDA-cleared, and available now. The reason most postmenopausal women on Wegovy and Mounjaro are not getting it is structural: their prescribing telehealth provider is not allowed, equipped, or incentivized to discuss hormone therapy.

The January 2026 Lancet publication was led by Dr. Regina Castaneda and Dr. Maria Daniela Hurtado of the Mayo Clinic's Precision Medicine for Obesity Program in Jacksonville, Florida.¹ The retrospective cohort study pulled electronic health record data from 120 postmenopausal women with BMI 27 or higher, treated with tirzepatide for at least 12 months between June 2022 and May 2024. Forty of the women were also on hormone therapy. Eighty matched controls were on tirzepatide alone.

The headline result: women in the hormone therapy group lost 19.2% of body weight at last follow-up. Women on tirzepatide alone lost 14.0%. That is a 35% relative difference in weight loss outcomes, achieved without changing the tirzepatide dose, the diet protocol, or the activity recommendation. The HRT group also showed better cardiometabolic improvements across HbA1c, triglycerides, and total cholesterol.

This finding does not stand alone. Dr. Hurtado's earlier 2024 Menopause journal study used the same retrospective methodology on 106 postmenopausal women on semaglutide.² At 12 months, hormone therapy users had achieved 16% body weight loss versus 12% in non-users, with statistically significant differences at every measurement point. The semaglutide data preceded the tirzepatide data by 18 months and predicted what the Lancet team would later confirm.

What the published research describes aligns with what we assess in clinical practice: postmenopausal women on a GLP-1 who add appropriately prescribed hormone therapy may see improved weight-loss response, consistent with the Mayo Clinic findings. Individual results vary, and no specific outcome can be promised. What the data supports is that estrogen status is a measurable, modifiable variable in how postmenopausal women respond to GLP-1 medications, and it is one most telehealth weight-loss programs never evaluate.

The pivotal trials that established tirzepatide and semaglutide as obesity treatments enrolled younger women than the population that needs these medications most. SURMOUNT-1, the tirzepatide trial, had a mean enrollment age in the early 50s.⁴ STEP-1, the semaglutide trial, was similar.⁵ The headline weight loss numbers, 15 to 20 percent for tirzepatide and approximately 15 percent for semaglutide, were achieved in a population skewed toward premenopausal and perimenopausal women.

Postmenopausal women are not the same patient population. Estrogen loss after the menopausal transition changes the body's response to GLP-1 receptor agonists in three observable ways. Visceral fat accumulation accelerates. Lean mass loss accelerates. And the hypothalamic appetite signaling that GLP-1 medications target becomes less responsive because estrogen receptors on hypothalamic neurons are no longer being stimulated by circulating estradiol. The result is the plateau women experience around month six to nine on the medication, and the lower ceiling on total weight loss compared to the trial-reported numbers.

The mechanism explanation matters because it tells you the finding is biologically plausible, not a statistical coincidence. Estrogen receptors are expressed on hypothalamic appetite centers, specifically in the arcuate nucleus and the paraventricular nucleus. These are the same neuroanatomical regions where GLP-1 receptor agonists exert their appetite-suppressing effects. When estradiol drops below physiologic levels in untreated postmenopause, the GLP-1 signal is operating on partially desensitized neurons.

Estrogen also drives thermogenesis in brown adipose tissue. Brown fat metabolic activity declines after menopause and recovers measurably with HRT use. That recovered thermogenic capacity is part of the explanation for the body composition improvements seen in the HRT group of the Lancet study.

When postmenopausal patients ask me which GLP-1 is best for them, the honest answer is that it depends on what they are already on and what they are aiming for.

Both medications produce more weight loss when paired with hormone therapy. The dual-mechanism tirzepatide produces the largest absolute effect.

The practical implication: women who plateau on semaglutide often benefit from switching to tirzepatide, particularly if they are also adding HRT at the same transition point. The combination of tirzepatide plus HRT produces the closest match to what younger women experienced on tirzepatide alone in the pivotal trial.

My Solcara transition protocol for women moving from semaglutide to tirzepatide while initiating HRT: start HRT first to allow four to six weeks for estradiol stabilization, then transition the GLP-1 with a 14-day washout and titration restart on tirzepatide. Most women tolerate the transition cleanly. The few who do not tend to be sensitive to the lower-end GI side effects of tirzepatide. Those patients we hold on semaglutide and reassess at six months with the added HRT effect alone.

The safety question is the question Charleston women bring to me most often. The Mayo Clinic / Lancet study found no increased adverse events in the combined HRT plus tirzepatide group compared to tirzepatide alone. Cardiometabolic markers improved in the HRT group. The FDA's February 2026 removal of the boxed warning from menopausal hormone therapy products, covered in our companion piece on the FDA HRT label change, clarified the regulatory environment for HRT use in appropriate-candidate women.

Required baseline workup for combined therapy includes a comprehensive metabolic panel, lipid panel with ApoB, HbA1c, fasting insulin, comprehensive hormone panel (estradiol, FSH, LH, progesterone, testosterone, SHBG, DHEA-S, cortisol), thyroid panel, breast and pelvic exam if not done in the past 12 months, and mammography current per age guidelines. Lab cadence after initiation: month 3, month 6, month 9, month 12, then every 6 months. Each follow-up draws the cardiometabolic panel and CBC, CMP, and lipase (the pancreatitis marker for any patient on a GLP-1).

This is the protocol I use. It is not the protocol most telehealth weight loss programs use. The difference matters because the combined therapy involves two prescribing systems, hormone therapy and a GLP-1, that interact. The patient deserves one clinician monitoring both rather than two disconnected prescribers each managing half the picture.

Three questions decide whether combined HRT and GLP-1 therapy is worth pursuing. If you can clear all three, you are likely a candidate.

If you clear all three questions, the next step is a clinical workup, not an internet diagnosis. Real candidacy requires the labs, the history, and the conversation. The questions above tell you whether the conversation is worth having.

Solcara's combined HRT plus GLP-1 protocol starts with a 90-minute initial consultation that covers full medical history, current medications including any existing GLP-1 prescription from another provider, menopausal status, and longevity goals. We draw the comprehensive workup described in the safety chapter above. We assess body composition with the same equipment used for our longevity panels rather than the bathroom scale and BMI that telehealth weight loss clinics rely on.

If candidacy clears, the combined protocol initiates with HRT first. The most common starting protocol for women with an intact uterus is transdermal estradiol patch combined with oral micronized progesterone, cycled or continuous depending on her preference and symptom pattern. For women post-hysterectomy, transdermal estradiol alone. The GLP-1 medication continues at her current dose if she is already on one, or initiates with the standard titration schedule if she is new to GLP-1 therapy. Learn more about Solcara's bioidentical hormone replacement therapy services.

Follow-up cadence: six weeks for the initial titration and tolerance check, then quarterly. Lab monitoring at months 3, 6, 9, 12, then every six months. Direct text and patient portal access between appointments for any concerns. Bidirectional communication with any specialty providers, oncology, cardiology, or primary care, where indicated.

The concierge model means same-week scheduling, no telehealth-only constraint, and the ability to see patients in person at either of our Charleston locations: Mount Pleasant (496 Bramson Court, Suite 120) or the downtown Longevity Club (163 Rutledge Avenue, Suite 202). This is the in-person, comprehensive alternative to the monthly telehealth GLP-1 prescription with no hormone therapy assessment, no body composition tracking, and no longitudinal cardiometabolic monitoring.

The questions Charleston women bring up most often. Click any question to read Ashley's answer.